Shares of ABIOMED, Inc. (NASDAQ:ABMD) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $231.90 and last traded at $230.27, with a volume of 231500 shares. The stock had previously closed at $228.18.
ABMD has been the topic of a number of research reports. SunTrust Banks initiated coverage on ABIOMED in a research note on Friday, September 29th. They issued a “buy” rating and a $195.00 price objective on the stock. Jefferies Group lifted their price objective on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research note on Friday, September 29th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective on the stock in a research note on Tuesday, November 7th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of ABIOMED in a research note on Thursday, January 4th. Finally, BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $210.50.
The company has a market capitalization of $10,300.12, a price-to-earnings ratio of 116.41, a P/E/G ratio of 3.07 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20.
In other news, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now owns 39,532 shares in the company, valued at approximately $7,079,390.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of ABMD. Crow Point Partners LLC purchased a new position in ABIOMED during the 4th quarter valued at $120,000. Cerebellum GP LLC purchased a new position in ABIOMED during the 4th quarter valued at $127,000. Rehmann Capital Advisory Group purchased a new position in ABIOMED during the 3rd quarter valued at $202,000. Sigma Planning Corp purchased a new position in ABIOMED during the 3rd quarter valued at $206,000. Finally, Dorsey & Whitney Trust CO LLC purchased a new position in ABIOMED during the 3rd quarter valued at $215,000. Institutional investors own 90.52% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ABIOMED (ABMD) Sets New 52-Week High at $231.90” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/abiomed-abmd-sets-new-52-week-high-at-231-90/1868481.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.